SG11202105863PA - Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio - Google Patents
Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratioInfo
- Publication number
- SG11202105863PA SG11202105863PA SG11202105863PA SG11202105863PA SG11202105863PA SG 11202105863P A SG11202105863P A SG 11202105863PA SG 11202105863P A SG11202105863P A SG 11202105863PA SG 11202105863P A SG11202105863P A SG 11202105863PA SG 11202105863P A SG11202105863P A SG 11202105863PA
- Authority
- SG
- Singapore
- Prior art keywords
- oxopyrrolidin
- butanamide
- synergistic compositions
- racemic ratio
- racemic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18210106 | 2018-12-04 | ||
| PCT/EP2019/083594 WO2020115093A1 (en) | 2018-12-04 | 2019-12-04 | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105863PA true SG11202105863PA (en) | 2021-07-29 |
Family
ID=64604549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105863PA SG11202105863PA (en) | 2018-12-04 | 2019-12-04 | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220047548A1 (en) |
| EP (1) | EP3890833B1 (en) |
| JP (1) | JP2022510363A (en) |
| KR (1) | KR20210099567A (en) |
| CN (1) | CN113164767A (en) |
| AU (1) | AU2019391309A1 (en) |
| BR (1) | BR112021010739A2 (en) |
| CA (1) | CA3117350A1 (en) |
| CO (1) | CO2021007055A2 (en) |
| EA (1) | EA202191485A1 (en) |
| EC (1) | ECSP21040300A (en) |
| ES (1) | ES2953785T3 (en) |
| HU (1) | HUE062575T2 (en) |
| IL (1) | IL283441A (en) |
| JO (1) | JOP20210082A1 (en) |
| MX (1) | MX2021006243A (en) |
| PL (1) | PL3890833T3 (en) |
| SG (1) | SG11202105863PA (en) |
| WO (1) | WO2020115093A1 (en) |
| ZA (1) | ZA202102701B (en) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412358D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| EP1034826A1 (en) | 1999-03-05 | 2000-09-13 | Reuter Chemische Apparatebau | Co-crystallization process |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| ITMI20030573A1 (en) | 2003-03-24 | 2004-09-25 | Nikem Research Srl | NOOTROPIC ACTION COMPOUNDS, THEIR PREPARATION, |
| CA2488325C (en) * | 2004-11-22 | 2010-08-24 | Apotex Pharmachem Inc. | Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
| CA2657571A1 (en) * | 2006-07-25 | 2008-01-31 | Zach System S.P.A. | Process for the preparation of levetiracetam |
| EP2215073A4 (en) | 2007-10-31 | 2011-04-06 | Merck Sharp & Dohme | Modulation of sleep with nr2b receptor antagonists |
| EP2098526B1 (en) | 2008-02-22 | 2014-01-15 | Neurotune AG | Nitrogen-containing bicyclic compounds active on chronic pain conditions |
| EP2671858A1 (en) * | 2012-06-08 | 2013-12-11 | Université Catholique De Louvain | Process for chiral resolution of etiracetam |
| JOP20190251A1 (en) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio |
-
2019
- 2019-12-04 ES ES19813837T patent/ES2953785T3/en active Active
- 2019-12-04 JO JOP/2021/0082A patent/JOP20210082A1/en unknown
- 2019-12-04 EA EA202191485A patent/EA202191485A1/en unknown
- 2019-12-04 CA CA3117350A patent/CA3117350A1/en active Pending
- 2019-12-04 MX MX2021006243A patent/MX2021006243A/en unknown
- 2019-12-04 CN CN201980076384.6A patent/CN113164767A/en active Pending
- 2019-12-04 SG SG11202105863PA patent/SG11202105863PA/en unknown
- 2019-12-04 PL PL19813837.2T patent/PL3890833T3/en unknown
- 2019-12-04 HU HUE19813837A patent/HUE062575T2/en unknown
- 2019-12-04 US US17/299,928 patent/US20220047548A1/en active Pending
- 2019-12-04 JP JP2021531433A patent/JP2022510363A/en active Pending
- 2019-12-04 KR KR1020217016689A patent/KR20210099567A/en unknown
- 2019-12-04 BR BR112021010739-8A patent/BR112021010739A2/en unknown
- 2019-12-04 WO PCT/EP2019/083594 patent/WO2020115093A1/en unknown
- 2019-12-04 EP EP19813837.2A patent/EP3890833B1/en active Active
- 2019-12-04 AU AU2019391309A patent/AU2019391309A1/en active Pending
-
2021
- 2021-04-22 ZA ZA2021/02701A patent/ZA202102701B/en unknown
- 2021-05-25 IL IL283441A patent/IL283441A/en unknown
- 2021-05-28 CO CONC2021/0007055A patent/CO2021007055A2/en unknown
- 2021-06-03 EC ECSENADI202140300A patent/ECSP21040300A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE062575T2 (en) | 2023-11-28 |
| CN113164767A (en) | 2021-07-23 |
| EA202191485A1 (en) | 2021-08-30 |
| KR20210099567A (en) | 2021-08-12 |
| EP3890833B1 (en) | 2023-06-07 |
| IL283441A (en) | 2021-07-29 |
| PL3890833T3 (en) | 2023-09-18 |
| EP3890833C0 (en) | 2023-06-07 |
| AU2019391309A1 (en) | 2021-05-20 |
| BR112021010739A2 (en) | 2021-08-24 |
| ECSP21040300A (en) | 2021-07-30 |
| WO2020115093A1 (en) | 2020-06-11 |
| ZA202102701B (en) | 2023-10-25 |
| CO2021007055A2 (en) | 2021-06-10 |
| US20220047548A1 (en) | 2022-02-17 |
| JOP20210082A1 (en) | 2023-01-30 |
| EP3890833A1 (en) | 2021-10-13 |
| MX2021006243A (en) | 2021-08-11 |
| CA3117350A1 (en) | 2020-06-11 |
| ES2953785T3 (en) | 2023-11-16 |
| JP2022510363A (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256611A1 (en) | Natural preservatives and antimicrobial agents, including compositions thereof | |
| IL292961A (en) | Cyclooctatetraene containing dyes and compositions | |
| IL270833B (en) | Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio | |
| IL271758A (en) | Statin compositions and methods for use in treating synucleinopathies | |
| ZA202103276B (en) | Bioflavonoid compositions and their use | |
| GB2599803B (en) | Methods and compositions for promoting health in a subject | |
| IL283441A (en) | Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio | |
| EP3920795A4 (en) | Instrumented mouthguard devices and components configured for use in instrumented mouthguard devices | |
| ZA202100525B (en) | Synergistically effective herbicide composition comprising pyridate and at least one defined 4-hppd inhibitor | |
| GB201901413D0 (en) | Compositions and their use | |
| SG11202104032PA (en) | Cosmetic composition in multiple emulsion formulation | |
| ZA202104787B (en) | Preservative systems and compositions comprising them | |
| EP4097160C0 (en) | Macromolecular compounds and use thereof in compositions | |
| IL299029A (en) | Matured three-dimensional printed compositions and uses thereof | |
| PL3930727T3 (en) | Antioxidant composition comprising polydatin and acetylcysteine | |
| ZA202207279B (en) | Composition rich in polyphenols and flavonoids for use as a biostimulant and antimicrobial for use in agriculture | |
| GB202014427D0 (en) | Composition and use | |
| GB2571766B (en) | Dental composition and dental paste comprising same | |
| GB201906765D0 (en) | Improvement in and relating | |
| GB201910419D0 (en) | My jigsaw puzzle table in a box | |
| AU2019900364A0 (en) | Instrumented mouthguard devices and components configured for use in instrumented mouthguard devices | |
| AU2019902828A0 (en) | Compositions and methods for promoting health in a subject | |
| GB201905593D0 (en) | Compositions and uses thereof | |
| AU2019901142A0 (en) | Methods and compositions for promoting health in a subject | |
| GB202016863D0 (en) | Microrna-29 compounds, compositions and uses in therapy |